Central Deficiency of Corticotropin-Releasing Hormone Receptor Type 1 (CRH-R1) Abolishes Effects of CRH on NREM But Not on REM Sleep in Mice

被引:36
|
作者
Romanowski, Christoph P. N. [1 ]
Fenzl, Thomas [1 ]
Flachskamm, Cornelia [1 ]
Wurst, Wolfgang [2 ]
Holsboer, Florian [1 ]
Deussing, Jan M. [1 ]
Kimura, Mayumi [1 ]
机构
[1] Max Planck Inst Psychiat, D-80804 Munich, Germany
[2] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Munich, Germany
关键词
CRH; stress; wake; NREM; REM; sleep regulation; conditional CRH-R1 knockout mice; BEHAVIORAL-RESPONSES; REDUCED ANXIETY; STRESS-RESPONSE; CENTRAL NUCLEUS; NERVOUS-SYSTEM; BRAIN; MOUSE; NEURONS; RATS; DETERMINANTS;
D O I
10.1093/sleep/33.4.427
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Study Objectives: Corticotropin-releasing hormone (CRH) is the major activator of the hypothalamic-pituitary-adrenocortical (HPA) system and orchestrates the neuroendocrine, autonomous as well as behavioral responses to stress. Many studies suggest an influence of CRH on sleep-wake regulation even in the absence of stressors. However, none of these studies yet clearly distinguished between central and peripheral effects of CRH. Therefore, we investigated in CNS-specific CRH receptor type 1 deficient mice whether centrally administered CRH could induce its sleep-wake modulatory effects without peripheral induction of HPA activity. Design: Male mice (C57BL/6J, CNS-specific CRH-R1 knockout [CKO] mice and their control littermates [CL]) were intracerebroventricularily (i.c.v.) injected with vehicle or 3 different doses of CRH shortly before the beginning of the light period. Electroencephalogram (EEG) and electromyogram (EMG) were monitored to compare the effects of CRH on vigilance states with or without presence of central CRH-R1. To quantify HPA-axis reactivity to CRH injections in CKO and CL animals, blood samples were analyzed to determine plasma corticosterone concentrations. Results: I.c.v, injections of CRH promoted wakefulness while decreasing NREMS in C57BL/6J and CRH-R1 CL animals, whereas such changes were not exerted in CKO mice. However, REMS suppression after CRH application persisted in all animals. I.c.v. injected CRH increased plasma corticosterone levels in both CL and CKO mice. Conclusions: The results demonstrated that CRH has a major impact on wake and NREMS regulation which is predominantly mediated through central CRH-R1. Peripheral actions of CRH, i.e., elevated HPA activity, may interfere with its central effects on REMS but not on NREMS suppression.
引用
收藏
页码:427 / 436
页数:10
相关论文
共 50 条
  • [1] Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists
    Beck, JP
    Arvanitis, AG
    Curry, MA
    Rescinito, JT
    Fitzgerald, LW
    Gilligan, PJ
    Zaczek, R
    Trainor, GL
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (07) : 967 - 972
  • [2] Corticotropin-releasing hormone (CRH) and CRH receptor 1 gene expression in vitiligo
    Shaker, O. G.
    Eltahlawi, S. M. R.
    Tawfic, S. O.
    Eltawdy, A. M.
    Bedair, N. I. E.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2016, 41 (07) : 734 - 740
  • [3] Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response
    Orand, Alexa
    Naliboff, Bruce
    Gadd, Malin
    Shih, Wendy
    Ju, Tiffany
    Presson, Angela P.
    Mayer, Emeran A.
    Chang, Lin
    PSYCHONEUROENDOCRINOLOGY, 2016, 73 : 133 - 141
  • [4] Gestational age and labor-associated changes in the placental mRNA expression of corticotropin releasing hormone (CRH) and CRH-receptor 1 (CRH-R1).
    Takae, K
    Unno, N
    Ogiso, Y
    Taketani, Y
    JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2004, 11 (02) : 352A - 353A
  • [5] Characterization of a novel brain penetrant, orally available corticotropin-releasing hormone receptor 1 (CRH-R1) antagonist for treatment of alcoholism
    Thorsell, Annika
    Cippitelli, Andrea
    Ciccocioppo, Roberto
    Heilig, Markus
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S73 - S74
  • [6] MTIP: A novel brain penetrant, orally available corticotropin-releasing hormone receptor 1 (CRH-R1) antagonist for treatment of alcoholism
    Gehlert, D. R.
    Cippitelli, A.
    Thorsell, A.
    Le, A. D.
    Hipskind, P. A.
    Hamdouchi, C.
    Lu, J.
    Hembre, E. J.
    Cramer, J.
    Song, M.
    McKinzie, D.
    Morin, M.
    Ciccocioppo, R.
    Heilig, M.
    NEUROPEPTIDES, 2008, 42 (01) : 117 - 117
  • [7] The role of the CRH type 1 receptor in autonomic responses to corticotropin-releasing hormone in the rat
    Nijsen, MJMA
    Croiset, G
    Stam, R
    Bruijnzeel, A
    Diamant, M
    de Wied, D
    Wiegant, VM
    NEUROPSYCHOPHARMACOLOGY, 2000, 22 (04) : 388 - 399
  • [8] MTIP:: a novel brain penetrant, orally available corticotropin-releasing hormone receptor 1 (CRH-R1) antagonist for treatment of alcoholism
    Gehlert, D. R.
    Cippitelli, A.
    Thorsell, A.
    Le, A. D.
    Hipskind, P. A.
    Hamdouchi, C.
    Lu, J.
    Hembre, E. J.
    Cramer, J.
    Song, M.
    McKinzie, D.
    Morin, M.
    Ciccocioppo, R.
    Heilig, M.
    ALCOHOL, 2008, 42 (04) : 338 - 338
  • [9] MTIP:: a novel brain penetrant, orally available corticotropin-releasing hormone receptor 1 (CRH-R1) antagonist for treatment of alcoholism
    Gehlert, D. R.
    Cippitelli, A.
    Thorsell, A.
    Le, A. D.
    Hipskind, P. A.
    Hamdouchi, C.
    Lu, J.
    Hembre, E. J.
    Cramer, J.
    Song, M.
    McKinzie, D.
    Morin, M.
    Ciccocioppo, R.
    Heilig, M.
    NEUROPEPTIDES, 2008, 42 (04) : 484 - 484
  • [10] Thiazolo[4,5-d]pyrimidine thiones and -ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists
    Beck, JP
    Curry, MA
    Chorvat, RJ
    Fitzgerald, LW
    Gilligan, PJ
    Zaczek, R
    Trainor, GL
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (08) : 1185 - 1188